Stock future

Investors are watching closely the companies that are working diligently to develop a COVID-19 vaccine. Many different biotech companies have put other projects on hold to focus mostly on a vaccine that could end the pandemic we are currently in. As an investor, there’s a lot of information out there and it’s hard to say which company will win the race. But being the first company to develop a vaccine may not mean it is the long-term winner if a different company produces a more effective one. Here’s a look at where the leaders stand currently.


Moderna has been a popular name since the start of the pandemic since it was the first to begin human trials on a vaccine. The company has received more than $450 million to support its process on developing a vaccine and they are currently in phase 3 of their trials. Indications are the trials have been mostly successful and tolerated very well by most trial participants. Moderna continues to be a viable option for an investor since it has been one of the leaders of developing a vaccine since March.


AstraZeneca didn’t enter the COVID-19 vaccine race as early as some companies, but they have made up for lost time with their efforts. They have collaborated with the University of Oxford to research, test, and monitor vaccine trials. Most of the results have been promising with a vast majority of participants developing antibodies that may neutralize the coronavirus. AstraZeneca was provided $1.2 billion for their efforts and their stock future continues to look promising as a result.


Inovio is another company that has been in the COVID-19 vaccine race since the beginning. While its testing has also been promising, the lack of information provided by the company regarding test participants and antibody results has hurt their stock futures. This is one of the reasons why they have not received significant funding for their vaccine development efforts. However, Inovio is still in the race and could be a good value buy for an investor.

BioNTech And Pfizer

BioNTech and Pfizer haven’t received significant funding for vaccine developments, but with the United States government pre-ordering 100 million doses of the vaccine, the stock futures look promising. Once their vaccine receives regulatory approval, it’s believed the U.S. government could order several hundred million more doses for billions of dollars. The BioNTech and Pfizer team is worth watching closely for investors.

Stock Investing Info can help you develop investment strategies surrounding the COVID-19 pandemic and vaccine development. The winner of the vaccine race may get a lot of the headlines, but it doesn’t guarantee they will be the long-term winner for an investor. As with any investments, looking at the long-term outlook is equally as important as the short-term. Be sure to contact us to stay up-to-date on the latest COVID-19 vaccine developments.

Leave a Reply